These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19190908)

  • 1. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
    Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
    Zang DY; Yang DH; Lee HW; Hwang SW; Song HH; Jung JY; Kwon JH; Kim HJ; Kim JH; Park SR; Kim MJ; Jang KM; Park CK; Kim JH; Lee BH
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):509-16. PubMed ID: 18481067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601).
    Nakayama N; Koizumi W; Sasaki T; Higuchi K; Tanabe S; Nishimura K; Katada C; Nakatani K; Takagi S; Saigenji K
    Oncology; 2008; 75(1-2):1-7. PubMed ID: 18719348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
    Kim YH; Seo HY; Jeen YT; Kim HK; Shim BY; Yang J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):253-60. PubMed ID: 18493761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
    Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
    Ozaki T; Tamura K; Satoh T; Kurata T; Shimizu T; Miyazaki M; Okamoto I; Nakagawa K; Fukuoka M
    Anticancer Res; 2007; 27(4C):2657-65. PubMed ID: 17695429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
    Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
    Fujiwara Y; Nishida T; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Yamamoto K; Moon JH; Mori M; Doki Y
    Anticancer Res; 2010 Apr; 30(4):1335-9. PubMed ID: 20530449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
    Park I; Lee JL; Ryu MH; Chang HM; Kim TW; Sym SJ; Lee SS; Jang G; Yoo C; Bae KS; Kang YK
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):473-80. PubMed ID: 19551382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
    Sato Y; Sagawa T; Ohnuma H; Hirakawa M; Takahashi Y; Hamaguchi K; Fujikawa K; Nobuoka T; Okamoto K; Miyamoto H; Muguruma N; Takemasa I; Takayama T
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):161-167. PubMed ID: 30406285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.